abbvie inc (ABBV:Euronext Paris)
Transactions by ABBVIE INC (ABBV) in the last 6 months
AbbVie Inc. (NYSE:ABBV) signed a definitive agreement to acquire Pharmacyclics Inc. (NasdaqGS:PCYC) from ProQuest Investments and others for $19.8 billion in cash and stock on March 4, 2015. Under the terms of the agreement, AbbVie will acquire all of the outstanding shares of Pharmacyclics through a tender offer, followed by a second-step merger. In the tender offer, AbbVie will acquire all of the outstanding shares of Pharmacyclics' common stock for $261.25 per share, ...
J.P. Morgan Securities LLC
AbbVie Inc. (NYSE:ABBV) acquired manufacturing site in Tuas Biomedical Park on November 20, 2014.
AbbVie Inc. (NYSE:ABBV) announces a share repurchase program. Under the program, the company will repurchase up to $5,000 million of the company's outstanding common stock. This authorization permits shares to be repurchased in open market or private transactions. The program has no time limit and may be discontinued at any time. The share repurchase authorization is expected to be completed over the next several years.
The Board of Directors of AbbVie Inc. has authorized ...
|Abbott Laboratories||$46.50 USD||-0.94|
|Amgen Inc||$154.88 USD||-4.72|
|AstraZeneca PLC||4,416 GBp||-71.00|
|Eli Lilly & Co||$68.41 USD||-2.18|
|Novo Nordisk A/S||kr321.10 DKK||+3.10|
|View Industry Companies|